Shorter waitlist times and improved graft survivals are observed in patients who accept hepatitis C virus+ renal allografts

Transplantation

Volumn 99, Issue 6, 2015, Pages 1192-1196

  Scalea, Joseph R ^a   Barth, Rolf N ^a   Munivenkatappa, Raghava ^a   Philosophe, Benjamin ^a   Cooper, Matthew ^a   Whitlow, Victoria ^a   Lamattina, John C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICAN AMERICAN; ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTENSION; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; WAITLIST TIME; ADULT; ADVERSE EFFECTS; COMPLICATION; DONOR; DONOR SELECTION; HOSPITAL ADMISSION; KAPLAN MEIER METHOD; KIDNEY FAILURE, CHRONIC; MULTIVARIATE ANALYSIS; PROCEDURES; RETROSPECTIVE STUDY; RISK FACTOR; TIME; TRANSMISSION; TRANSPLANTATION;

ADULT; DONOR SELECTION; FEMALE; GRAFT SURVIVAL; HEPATITIS C; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS; WAITING LISTS;

EID: 84930535959     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000479     Document Type: Article

References (15)

1. Annual Data Report. SRTR & OPTN, 2010.
2. Meyers CM, Seeff LB, Stehman-Breen CO, et al. Hepatitis C and renal disease: An update. Am J Kidney Dis 2003;42:631.
3. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, et al. Hepatitis C virus and death risk in hemodialysis patients. Am Soc Nephrol 2007;18:1584.
4. Nakayama E, Akiba T, Marumo F, et al. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. Am Soc Nephrol 2000;11:1896.
5. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999;29:257.
6. Bucci JR, Matsumoto CS, Swanson SJ, et al. Donor hepatitis C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J Am Soc Nephrol 2002;13:2974.
7. Wolfe RA, Roys EC, Merion RM. Trends in organ donation and transplantation in the united states, 1999-2008. AmJ Transplant 2009;10:961.
8. Kucirka LM, Singer AL, Ros RL, et al. Underutilization of hepatitis c-positive kidneys for hepatitis c-positive recipients. Am J Transplant 2010;10:1238.
9. Gane EJ. The natural history of recurrent hepatitis C. Liver Transpl 2008; 14:S36.
10. Maluf DG, Archer KJ, Mas VR. Kidney grafts from HCV-positive donors: Advantages and disadvantages. Transplant Proc 2010;42:2436.
11. Luan FL, Schaubel DE, Zhang H, et al. Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C. Transplantation 2008;85:160.
12. Abbott KC, Bucci JR, Matsumoto CS, et al. Hepatitis c and renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 2003;14:2908.
13. Kucirka LM, Peters TG, Segev DL. Impact of donor hepatitis C virus infection status on death and need. for liver transplant in hepatitis C virus-positive kidney transplant recipients. Am J Kidney Dis 2012;60:112.
14. Ng FL, Holt DW, Chang RW, et al. Black renal transplant recipients have poorer long-term graft survival than CYP3A5 expressers from other ethnic groups. Nephrol Dial Transplant 2010;25:628.
15. Pereira BJG, Natov SN, Bouthot BA, et al. The New England Organ Bank Hepatitis C Study Group. Effect of hepatitis C infection and renal transplantation on survival in end-stage renal disease. Kidney Int 1998;53:1374.